Table 1.
Population and clinical model inputs.
| Input | Value | Source |
|---|---|---|
| Population | ||
| Eligible population size | 60,378 | Unpublished 2018 data from Swiss Health Observatory |
| Male proportion | 51.4% | HUG Psychiatry Department |
| Average age (years) | 46.5 | HUG Psychiatry Department |
| HCV prevalence (population currently tested) | 25.7% | HUG Psychiatry Department |
| HCV prevalence (population not currently tested) | 3.5% | HUG Psychiatry Department |
| Proportion who present for testing (current screening) | 38.3% | HUG Psychiatry Department |
| Screening and diagnosis | ||
| RNA PCR sensitivity | 1 | Assumed |
| RNA PCR specificity | 1 | Assumed |
| Proportion of tests in which confirmation of diagnosis is requested | 3.4% | HUG audit on quality of laboratory results |
| Proportion of patients who receive an antibody test as part of test package | 39.0% | HUG audit on quality of laboratory results |
| Proportion of patients who receive an RNA test as part of test package | 94.9% | HUG audit on quality of laboratory results |
| Probably of accepting invitation to screening/testing | 89.0% | Point of care, HUG Psychiatry Department |
| Probably of collecting test results | 95.0% | Point of care, HUG Psychiatry Department |
| Probably of initiating treatment | 84.0% | Point of care, HUG Psychiatry Department |
| Disutility of HCV-positive result | 0.02 | Based on estimate by Singer and Younossi28 (from Rodger et al. 1999)29 |
| Treatment | ||
| Lifetime QALYs per infected person (no antiviral treatment) | 16.5 | Scott et al. 201618 |
| Lifetime QALYs per infected person (early treatment) | 21.7 | Scott et al. 201618 |
HCV, hepatitis C virus; HUG, University Hospitals of Geneva; PCR, polymerase chain reaction; QALY, quality-adjusted life-year; RNA, ribonucleic acid.